A third derivative suit has been filed against kidney drug developer Tricida Inc. in the U.S. District Court for the District of Delaware, alleging company leadership’s misleading statements caused stock prices to plummet.

The complaint filed May 27 by Ryan M. Ernst of Bielli & Klauder echoes the two others made this year in its claims that San Francisco-based Tricida officials promoted Veverimer, the company’s only drug candidate, as well on its way to approval despite knowing the Food and Drug Administration wasn’t actually likely to approve the drug, which is aimed at treating chronic kidney disease.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]